A study lead by Yin and colleagues showed that the immuno-blocking bispecific antibody FL-BsAb1/17, which targets IL-1β and IL-17A, reduced lesions of DSS-induced ulcerative colitis in mice and significantly reduced the degree of fibrosis in vivo, suggesting that IL-1 and/or IL-17 are pivotal contributors to inflammatory and fibrotic diseases such as PSC and IBD [164]. Here, IL1A is linked to inflammatory bowel disease.